Core Viewpoint - The stock of United Imaging Healthcare (688271) has experienced a decline, with a closing price of 131.11 yuan on November 19, 2025, down by 2.34% [1] Group 1: Stock Performance - On November 19, 2025, the stock had a turnover rate of 0.4%, with a trading volume of 32,800 hands and a transaction amount of 435 million yuan [1] - The net outflow of main funds was 14.797 million yuan, accounting for 3.4% of the total transaction amount, while retail investors saw a net outflow of 36.92 thousand yuan, representing 0.08% of the total [1][2] Group 2: Financial Metrics - As of the third quarter of 2025, United Imaging Healthcare reported a main business revenue of 8.859 billion yuan, a year-on-year increase of 27.39%, and a net profit attributable to shareholders of 1.12 billion yuan, up 66.91% [3] - The company’s gross profit margin stands at 47.02%, while the net profit margin is 12.44% [3] Group 3: Industry Comparison - United Imaging Healthcare's total market capitalization is 108.055 billion yuan, significantly higher than the industry average of 11.279 billion yuan, ranking 2nd in the industry [3] - The company has a price-to-earnings ratio of 72.34, which is higher than the industry average of 56.7, ranking 64th in the industry [3] Group 4: Analyst Ratings - In the past 90 days, 27 institutions have rated the stock, with 20 buy ratings and 7 hold ratings, and the average target price set by institutions is 175.45 yuan [4]

Core Insights - Chinese enterprises are experiencing a new wave of globalization, with a focus on expanding into overseas markets and enhancing their core technologies, exemplified by the recent launch of the uSONIQUE ultrasound series by United Imaging Healthcare [2][3] - The role of CFOs is evolving, requiring them to develop capabilities in global resource allocation, data-driven strategic judgment, and compliance under international regulations [2] - The global landscape is shifting from a developed-country-centric model to a more decentralized and sustainable collaborative structure, presenting both opportunities and challenges for Chinese companies [4] Company Developments - United Imaging Healthcare plans to launch its full line of ultrasound products in both domestic and international markets, with ongoing applications for CE and FDA certifications [3] - The ultrasound equipment market in China is projected to grow from 9.02 billion in 2020 to 21.62 billion by 2030, with a compound annual growth rate of 8.1% [3] - Despite the growth potential, the high-end ultrasound market remains dominated by foreign companies, with domestic market share below 40% [3] Industry Trends - Chinese enterprises are undergoing a deep restructuring phase characterized by three transformations: cognitive, operational, and strategic [4] - The expansion of Chinese companies is marked by significant growth in direct foreign investment and mergers and acquisitions, with diverse practices including brand development and technological integration [4] - The challenges faced by companies in their internationalization efforts include supply chain restructuring, geopolitical tensions, rapid technological changes, and complex compliance regulations [6][8] Financial Management Evolution - The role of CFOs is shifting from traditional financial management to becoming Chief Value Officers, emphasizing the importance of sustainability and long-term value creation [6] - The financial management landscape is expected to undergo significant changes, including the rise of AI in accounting and a focus on ESG reporting [7] - Companies must balance cost optimization with compliance management to enhance the sustainability and resilience of their global supply chains [8]

Core Viewpoint - The stock of United Imaging Healthcare has experienced fluctuations, with a recent decline of 2.00% and a total market capitalization of 108.43 billion yuan, reflecting a mixed performance in the stock market [1]. Financial Performance - For the period from January to September 2025, United Imaging Healthcare reported a revenue of 8.859 billion yuan, representing a year-on-year growth of 27.39%, and a net profit attributable to shareholders of 1.120 billion yuan, which is a 66.91% increase compared to the previous year [2]. - The company has distributed a total of 641 million yuan in dividends since its A-share listing [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for United Imaging Healthcare increased to 32,400, marking a 96.28% rise from the previous period, while the average number of circulating shares per person decreased by 29.23% to 25,444 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 19.036 million shares, a decrease of 2.9809 million shares from the previous period [3].

截至2025年11月18日收盘，联影医疗(688271)报收于134.25元，上涨0.19%，换手率0.5%，成交量4.08万 手，成交额5.44亿元。 当日关注点 公司公告汇总 联影医疗持股5%以上股东宁波梅山保税港区影聚投资管理合伙企业（有限合伙）、宁波梅山保税港区 影力投资管理合伙企业（有限合伙）及其一致行动人于2025年9月1日至11月14日期间通过集中竞价方式 合计减持公司股份5,478,055股，占公司总股本的0.66%。本次权益变动后，上述股东合计持股比例由 6.62%下降至5.96%，权益变动触及1%刻度。本次减持为履行已披露的减持计划，不触及要约收购，不 会导致公司控股股东及实际控制人发生变化，对公司治理结构及持续经营无重大影响。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：11月18日主力资金净流出3508.96万元，占总成交额6.46%。 来自公司公告汇总：联影医疗持股5%以上股东及其一致行动人减持5,478,055股，持股比例由 6.62%降至5.96%，权益变动触及1%刻度。 交易信息 ...

Group 1 - The company announced the election of Mr. Zhang Yue as the chairman [2]

Core Points - The company announced the convening of its fifth board meeting on November 18, 2025, to review the proposal for granting restricted stock to incentive recipients [1] - The grant date is set for November 18, 2025, with a grant price of 17.00 yuan per share [1] - A total of 3,275,264 shares of restricted stock will be granted to 110 incentive recipients [1]

Core Viewpoint - The stock of United Imaging Healthcare (688271) has shown a slight increase, with a closing price of 134.25 yuan on November 18, 2025, reflecting a 0.19% rise, amidst mixed capital flows [1][2]. Financial Performance - For the first three quarters of 2025, United Imaging Healthcare reported a main business revenue of 8.859 billion yuan, a year-on-year increase of 27.39% [3]. - The net profit attributable to shareholders for the same period was 1.12 billion yuan, up 66.91% year-on-year [3]. - The third quarter of 2025 saw a single-quarter main business revenue of 2.843 billion yuan, representing a 75.41% increase year-on-year [3]. - The net profit for the third quarter was 122 million yuan, a significant rise of 143.8% year-on-year [3]. - The company’s gross profit margin stands at 47.02%, while the net profit margin is 12.44% [3]. Market Position - United Imaging Healthcare has a total market capitalization of 110.643 billion yuan, ranking 2nd in the medical device industry [3]. - The company’s net assets amount to 20.805 billion yuan, placing it 3rd in the industry [3]. - The price-to-earnings ratio (P/E) is 74.08, which is higher than the industry average of 55.31, ranking 64th [3]. - The price-to-book ratio (P/B) is 5.32, compared to the industry average of 4.04, ranking 104th [3]. Capital Flow Analysis - On November 18, 2025, the net outflow of main capital was 35.0896 million yuan, accounting for 6.46% of the total transaction amount [1][2]. - Retail investors saw a net inflow of 15.9243 million yuan, representing 2.93% of the total transaction amount [1][2]. - Over the past five days, the stock has experienced significant fluctuations in capital flow, with notable net outflows on several days [2]. Analyst Ratings - In the last 90 days, 27 institutions have provided ratings for United Imaging Healthcare, with 20 buy ratings and 7 hold ratings [4]. - The average target price set by institutions over the past 90 days is 175.45 yuan [4].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688271 证券简称：联影医疗公告编号：2025-046 联影医疗关于持股5%以上股东权益变动触及1%刻度的提示性公告 投资者及其一致行动人宁波梅山保税港区影聚投资管理合伙企业（有限合伙）、宁波梅山保税港区影力 投资管理合伙企业（有限合伙）、宁波梅山保税港区影健投资管理合伙企业（有限合伙）、宁波梅山保 税港区影康投资管理合伙企业（有限合伙）、上海影董企业管理合伙企业（有限合伙）保证向本公司提 供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ■ 一、信息披露义务人及其一致行动人的基本信息 1.身份类别 ■ 2.信息披露义务人信息 ■ 3.一致行动人信息 ■ 二、权益变动触及1%刻度的基本情况 2025年11月17日，公司收到股东宁波梅山保税港区影聚投资管理合伙企业（有限合伙）、宁波梅山保税 港区影力投资管理合伙企业（有限合伙）及其一致行动人发来的《减持权益变动告知函》，其于2025年 9月1日至2025年11月14日期间通过集中竞价方式合计减持公司股份 ...

Investment Rating - The report maintains a "Strong Buy" rating for the company [3]. Core Insights - The company reported a strong recovery in the domestic market and significant achievements in its globalization strategy, with a revenue of 8.859 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 27.39% [1]. - The net profit attributable to shareholders reached 1.12 billion yuan, up 66.91% year-on-year, while the net profit excluding non-recurring items was 1.053 billion yuan, reflecting a remarkable growth of 126.94% [1]. - The third quarter alone saw revenues of 2.843 billion yuan, a substantial increase of 75.41% year-on-year [1]. Financial Performance Summary - For the fiscal years 2023 to 2027, total revenue is projected to grow from 11.411 billion yuan in 2023 to 17.934 billion yuan in 2027, with year-on-year growth rates of 24%, -10%, 21%, 20%, and 20% respectively [2][9]. - The net profit attributable to shareholders is expected to increase from 1.974 billion yuan in 2023 to 2.739 billion yuan in 2027, with growth rates of 19%, -36%, 49%, 21%, and 21% respectively [2][9]. - The company’s earnings per share (EPS) is forecasted to rise from 2.40 yuan in 2023 to 3.32 yuan in 2027 [2][9]. Market Performance - The company achieved a revenue of 6.866 billion yuan in the domestic market for the first three quarters of 2025, marking a year-on-year increase of 23.70% [6]. - The overseas market revenue reached 1.993 billion yuan, with a year-on-year growth of 41.97%, indicating a growing contribution to overall revenue [6]. - The service business also showed strong growth, with a revenue increase of 28.44% year-on-year, reaching 1.243 billion yuan [6]. Profitability Metrics - The comprehensive gross margin for the third quarter of 2025 was reported at 45.09%, with a slight decline of 1.16 percentage points [6]. - The overall net profit margin improved significantly, reaching 4.02%, an increase of 21.68 percentage points [6]. - The report indicates that the company’s operational efficiency is continuously improving, supported by a robust supply chain and digital management system [6].

格隆汇11月17日丨联影医疗(688271.SH)公布，2025年11月17日，公司收到股东宁波梅山保税港区影聚 投资管理合伙企业（有限合伙）、宁波梅山保税港区影力投资管理合伙企业（有限合伙）及其一致行动 人发来的《减持权益变动告知函》，其于2025年9月1日至2025年11月14日期间通过集中竞价方式合计减 持公司股份547.81万股，占公司股份总数的0.66%。本次权益变动后，宁波梅山保税港区影聚投资管理 合伙企业（有限合伙）、宁波梅山保税港区影力投资管理合伙企业（有限合伙）及其一致行动人所持公 司股份比例由6.62%变动至5.96%，权益变动触及1%刻度。 ...